PERSANTINE TAB 50MG TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

DIPYRIDAMOLE

Mevcut itibaren:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

ATC kodu:

B01AC07

INN (International Adı):

DIPYRIDAMOLE

Doz:

50MG

Farmasötik formu:

TABLET

Kompozisyon:

DIPYRIDAMOLE 50MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100

Reçete türü:

Prescription

Terapötik alanı:

MISCELLANEOUS VASODILATATING AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0106621002; AHFS:

Yetkilendirme durumu:

CANCELLED POST MARKET

Yetkilendirme tarihi:

2011-03-03

Ürün özellikleri

_ _
_Product Monograph _
_Page 1 of 22 _
PRODUCT MONOGRAPH
Pr
PERSANTINE
®
Dipyridamole Tablets
Dipyridamole for Injection
50 mg and 75 mg tablets
5 mg/mL injectable ampoules
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Boehringer Ingelheim Canada Ltd.
5180 South Service Road
Burlington, ON L7L 5H4
Date of Preparation:
March 15, 1995
Date of Revision:
May 20, 2005
Submission Control No: 092334
BI BPI number: 0248-02 (tablets), 0150-04 (ampoules)
_ _
_Product Monograph _
_Page 2 of 22_
Table of Contents
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update
entire table”, click OK.]
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................5
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND
ADMINISTRATION................................................................................9
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND
STABILITY..........................................................................................11
SPECIAL HANDLING INSTRUCTIONS
.......................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................